|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.660 USD | -0.21% |
|
-.--% | +3.10% |
| Apr. 15 | Evotec Taps CureVac Executive as COO | MT |
| Jan. 06 | CureVac ends coverage after BioNTech acquisition | ![]() |
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
Revenues | 48.87M | 103M | 67.42M | 53.76M | 535M | ||
Total Revenues | 48.87M | 103M | 67.42M | 53.76M | 535M | ||
Cost of Goods Sold, Total | 14.12M | 238M | 159M | 116M | 106M | ||
Gross Profit | 34.75M | -135M | -91.55M | -62.45M | 430M | ||
Selling General & Admin Expenses, Total | 54.34M | 102M | 107M | 95.74M | 74.34M | ||
R&D Expenses | 114M | 816M | 62.55M | 116M | 153M | ||
Other Operating Expenses | 154K | -98K | -34.83M | -2.17M | -7.6M | ||
Other Operating Expenses, Total | 168M | 918M | 135M | 209M | 220M | ||
Operating Income | -134M | -1.05B | -226M | -272M | 210M | ||
Interest Expense, Total | -22.1M | -10.34M | -3.71M | - | - | ||
Interest And Investment Income | 2.07M | 10.1M | 4.01M | 15.41M | 12.36M | ||
Net Interest Expenses | -20.03M | -235K | 302K | 15.41M | 12.36M | ||
Currency Exchange Gains (Loss) | - | - | - | -1.21M | 842K | ||
Other Non Operating Income (Expenses) | - | - | - | 37K | 0 | ||
EBT, Excl. Unusual Items | -154M | -1.05B | -226M | -258M | 223M | ||
Restructuring Charges | - | - | - | - | -32.1M | ||
Gain (Loss) On Sale Of Assets | - | - | 785K | 1.2M | - | ||
Asset Writedown | - | - | -24.95M | -8.08M | - | ||
Insurance Settlements | - | - | 610K | 860K | - | ||
Other Unusual Items | 23.74M | 641M | 440K | 3.57M | - | ||
EBT, Incl. Unusual Items | -130M | -412M | -249M | -260M | 191M | ||
Income Tax Expense | -726K | -782K | -126K | 198K | 28.7M | ||
Earnings From Continuing Operations | -129M | -412M | -249M | -260M | 162M | ||
Net Income to Company | -129M | -412M | -249M | -260M | 162M | ||
Net Income - (IS) | -129M | -412M | -249M | -260M | 162M | ||
Net Income to Common Incl Extra Items | -129M | -412M | -249M | -260M | 162M | ||
Net Income to Common Excl. Extra Items | -129M | -412M | -249M | -260M | 162M | ||
Per Share Items | |||||||
Net EPS - Basic | -0.98 | -2.21 | -1.32 | -1.18 | 0.72 | ||
Basic EPS - Continuing Operations | -0.98 | -2.21 | -1.32 | -1.18 | 0.72 | ||
Basic Weighted Average Shares Outstanding | 132M | 186M | 189M | 221M | 224M | ||
Net EPS - Diluted | -0.98 | -2.21 | -1.32 | -1.18 | 0.72 | ||
Diluted EPS - Continuing Operations | -0.98 | -2.21 | -1.32 | -1.18 | 0.72 | ||
Diluted Weighted Average Shares Outstanding | 132M | 186M | 189M | 221M | 224M | ||
Normalized Basic EPS | -0.73 | -3.54 | -0.75 | -0.73 | 0.62 | ||
Normalized Diluted EPS | -0.73 | -3.54 | -0.75 | -0.73 | 0.62 | ||
Supplemental Items | |||||||
EBITDA | -128M | -1.04B | -210M | -255M | 223M | ||
EBITA | -132M | -1.05B | -223M | -268M | 212M | ||
EBIT | -134M | -1.05B | -226M | -272M | 210M | ||
EBITDAR | -128M | -1.04B | -209M | -255M | 223M | ||
Effective Tax Rate - (Ratio) | 0.56 | 0.19 | 0.05 | -0.08 | 15.03 | ||
Total Current Taxes | 403K | 1.03M | - | 118K | 19.11M | ||
Total Deferred Taxes | -1.13M | -1.82M | - | 80K | 9.59M | ||
Normalized Net Income | -95.99M | -658M | -141M | -161M | 139M | ||
Interest Capitalized | 1.99M | 2.93M | 2.29M | 2.38M | 2.31M | ||
Interest on Long-Term Debt | 3.65M | 4.66M | 4.51M | 2.38M | 2.31M | ||
Supplemental Operating Expense Items | |||||||
Selling and Marketing Expenses | 733K | 1.74M | 2.82M | 3.91M | 4.45M | ||
General and Administrative Expenses | 53.52M | 100M | 104M | 91.7M | 69.65M | ||
Research And Development Expense From Footnotes | 114M | 816M | 62.55M | 116M | 153M | ||
Net Rental Expense, Total | 78K | 158K | 142K | 125K | 237K | ||
Imputed Operating Lease Interest Expense | 224K | 399K | 192K | 56.61K | 109K | ||
Imputed Operating Lease Depreciation | -146K | -241K | -50K | 68.39K | 128K | ||
Stock-Based Comp., COGS (Total) | - | - | - | 340K | 295K | ||
Stock-Based Comp., R&D Exp. (Total) | 1.84M | 958K | 885K | 1.7M | 1.79M | ||
Stock-Based Comp., S&M Exp. (Total) | 4.95M | 295K | 184K | 275K | 98K | ||
Stock-Based Comp., G&A Exp. (Total) | 5.69M | 13.12M | 7.64M | 4.73M | 1.39M | ||
Stock-Based Comp., Other (Total) | 713K | 583K | 479K | 652K | 553K | ||
Total Stock-Based Compensation | 13.19M | 14.96M | 9.18M | 7.7M | 4.12M |
- Stock Market
- Stocks
- CVAC Stock
- Financials CureVac
- Income Statement
Select your edition
All financial news and data tailored to specific country editions

















